Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935085 · ClinicalTrials.gov registry record · Phase 2
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
A Phase 2 study, sponsored by AnaptysBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT05935085: Clinical Trial Phase 2 study, sponsored by AnaptysBio.
NCT05935085 is a Phase 2 study that was terminated before completion, run by AnaptysBio. The registered enrollment target is 201 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05935085, a Phase 2 study, was terminated before completion, sponsored by AnaptysBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Primary Outcome
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72.
Interventions
- DRUG Placebo
- DRUG ANB032
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2025-01-07 |
| Phase | Phase 2 |
Why NCT05935085 stopped before completion
NCT05935085 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05935085 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05935085 about?
NCT05935085 is a clinical study titled "This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).". This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT05935085?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2023-06-13. Estimated completion is 2025-01-07.
What interventions are being tested in trial NCT05935085?
The interventions under investigation include: Placebo (DRUG), ANB032 (DRUG).
Who is sponsoring clinical trial NCT05935085?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05935085's enrollment target sits among peer trials
201 302nd of 2000 higher than 1,697 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI